🇺🇸 NXY-059 in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 10

Most-reported reactions

1. Abdominal Distension — 1 report (10%)
2. Anaemia — 1 report (10%)
3. Ankle Fracture — 1 report (10%)
4. Atrial Fibrillation — 1 report (10%)
5. Atrioventricular Block Complete — 1 report (10%)
6. Atrioventricular Block First Degree — 1 report (10%)
7. Atrioventricular Block Second Degree — 1 report (10%)
8. Atrophy — 1 report (10%)
9. Blood Creatinine Increased — 1 report (10%)
10. Blood Urea Increased — 1 report (10%)

Source database →

Frequently asked questions

Is NXY-059 approved in United States?

NXY-059 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for NXY-059 in United States?

AstraZeneca is the originator. The local marketing authorisation holder may differ — check the official source linked above.